CHF Solutions (CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced increased utilization of its Aquadex therapy in patients affected by COVID-19. Product sales of the Aquadex therapy to six hospitals in New York City, the epicenter of the pandemic in the U.S., have increased over 300% in the last thirty days, as compared to the monthly-average for 2019. Ultrafiltration with the Aquadex SmartFlow™ system is an option for efficient fluid removal and rapid decongestion, and a way to optimize the volume status of these patients in a predictable way.

EDEN PRAIRIE, Minn., May 01, 2020 -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today.

CHF Solutions, Inc. (CHFS), today announced that, on May 20, 2020, the independent directors approved six equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to six individuals entering into employment with the company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with CHF Solutions, the six individuals, who were not previously employees or directors of CHF Solutions, received options to purchase an aggregate of 27,000 shares of the Company’s common stock.

CHF Solutions (CHFS) today announced the pricing of a registered direct offering of 3,597,880 shares of its common stock at a price of $0.4725 per share, for gross proceeds of approximately $1.7 million, prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 1,798,940 shares of the Company’s common stock. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering.

CHF Solutions (CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced the use of its Aquadex therapy in the treatment of patients infected with the coronavirus COVID-19. In the last week, critically ill patients in New York City and the state of Georgia, who have been infected with COVID-19, have been treated for volume overload using the Aquadex system. CHF Solutions expects increased demand for this ultrafiltration therapy as the rate of affected patients that are infected with COVID-19 is likely to increase.

CHF Solutions (CHFS), a small and growing medical device company dedicated to changing the lives of patients suffering from fluid overload, announced receipt of $1.66 million under the Paycheck Protection Program (PPP) under the federal Coronavirus Aid, Relief, and Economic Security (CARES) Act. This amount represents the full amount available to the company, based on its payroll expense. In addition, the company has received approximately $1.1 million in proceeds from the exercise of outstanding warrants.

EDEN PRAIRIE, Minn., May 12, 2020 -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended March 31, 2020, which included the following.

CHF Solutions (CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a publication highlighting the use of ultrafiltration for fluid management of critically ill patients suffering from COVID-19. “Fluid stewardship is likely to help reduce potential complications in critically ill patients with COVID-19,” said Amir Kazory, MD, FASN, FACC, a professor at the University of Florida, and one of the publication’s authors.

CHF Solutions (CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced that physicians on the frontlines of treating patients with COVID-19 have used Aquadex therapy for patients who need fluid removal between dialysis treatments as an alternative therapy when dialysis machines or trained dialysis personnel are not available. The real-world case studies and related discussion were presented during a physician-led webinar hosted by CHF Solutions on April 10. Dr. Daniel J. Goldstein, MD, FACS, FACC (Montefiore Medical Center, NY, NY) moderated the panel discussion which included Dr. Maria DeVita, M.D., FACP, FASN (Lenox Hill Hospital, NY, NY), Dr. Mehdi Oloomi, M.D. (Mount Sinai Medical Center, NY, NY) and Dr. Giovanni Piovesana (Phoebe-Putney Hospital, Albany, GA).

The Board of Directors believes approval of Proposal 3 is in the best interests of CHF Solutions and its stockholders because a reverse stock split may be necessary to maintain the listing of CHF Solutions’ common stock on the NASDAQ Capital Market (“Nasdaq”). A delisting of the common stock from Nasdaq could significantly impair CHF Solutions’ ability to raise additional capital, which may be needed to operate its business; it could result in lower prices for its common stock and larger spreads in the bid and ask prices for the common stock; and it could impact a stockholders ability to trade shares of common stock.

CHF Solutions (CHFS) today announced the Aquadex FlexFlow system has been licensed and approved for sale in India, making ultrafiltration therapy available for patients suffering from hypervolemia, or fluid overload, in one of the largest countries in the world. “We are pleased to have reached this important regulatory milestone and look forward to working with our distributor, Wayinia Lifesciences, to launch the Aquadex system in India this year and provide a safe and effective solution for heart failure patients, our primary clinical focus in this country,” said John Erb, chairman and CEO of CHF Solutions.

EDEN PRAIRIE, Minn., April 23, 2020 -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today.

EDEN PRAIRIE, Minn., April 08, 2020 -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today.

EDEN PRAIRIE, Minn., March 18, 2020 -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload,.

CHF Solutions (CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced that it has doubled the production staff that builds its next generation Aquadex SmartFlow consoles in response to increased demand from hospitals due to the coronavirus COVID-19. Following last week’s announcement regarding use of the Aquadex system in the treatment of critically ill patients, CHF Solutions has seen strong interest from additional hospitals and increased demand for this ultrafiltration therapy as the rate of affected patients continues to increase. “It is important for medical teams to quickly be aware of all of the tools available to treat these critically ill patients and have sufficient supply of life-saving devices,” said John Erb, CEO of CHF Solutions.

EDEN PRAIRIE, Minn., May 05, 2020 -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its first quarter 2020 financial results will be released on Tuesday, May 12, 2020..

CHF Solutions (CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for an adaptation to the Aquadex SmartFlow™ system to rapidly clear cytokines, including interleukin 6 (IL-6), from the blood. “We continue to receive positive feedback from medical staff using the Aquadex SmartFlow system with critically ill COVID-19 patients being treated with fluid resuscitation,” said John Erb, CEO of CHF Solutions. CHF Solutions, Inc. (CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.

CHF Solutions (CHFS) today announced the pricing of a registered direct offering of 4,161,392 shares of its common stock at a price to the public of $0.30 per share, for gross proceeds of approximately $1,248,000, prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 4,161,392 shares of the Company’s common stock. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering.

Shares of CHF Solutions (NASDAQ:CHFS) rose by 5% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 93.70% over the past year to ($0.37), which beat the estimate of ($1.26).Revenue of $1,630,000 rose by 34.16% year over year, which beat the estimate of $1,300,000.Outlook CHF Solutions hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 12, 2020View more earnings on CHFSTime: 09:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/k4srwz8bTechnicals Company's 52-week high was at $3.81Company's 52-week low was at $0.30Price action over last quarter: down 9.14%Company Overview CHF Solutions Inc is a medical device company. It focuses on commercializing the Aquadex FlexFlow System. The Aquadex FlexFlow System is used for temporary and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. It is designed to remove excess fluid ( primarily excess salt and water) from patients suffering from fluid overload who have failed diuretic therapy. The company only operating segment being Cardiac and coronary disease products.See more from Benzinga * 17 Healthcare Stocks Moving In Friday's Pre-Market Session * 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 18 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

CHF Solutions (CHFS) today announced the pricing of a registered direct offering of 5,130,228 shares of its common stock at a price to the public of $0.434 per share, for gross proceeds of approximately $2,226,000, prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 2,565,114 shares of the Company’s common stock. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering.